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Objectives The aim of this case match study was to compare the outcome of patients with paradoxical low-flow (left ventric-
ular ejection fraction [LVEF] 50% but stroke volume index 35 ml/m2), low-gradient (mean gradient [MG]
40 mm Hg), a priori severe (aortic valve area [AVA] 1.0 cm2) aortic stenosis (AS) (PLG-SAS group) with that
of patients with a severe AS (AVA 1.0 cm2) and consistent high-gradient (MG 40 mm Hg) (HG-SAS group)
and with that of patients with a moderate AS (AVA 1.0 cm2 and MG 40 mm Hg) (MAS group).
Background In patients with preserved LVEF, a discordance between the AVA (in the severe range) and the gradient (in the
moderate range) raises uncertainty with regard to the actual severity of the stenosis and thus the therapeutic
management of the patient.
Methods In a prospective cohort of AS patients with LVEF 50%, we identified 187 patients in the PLG-SAS group. These
patients were retrospectively matched: 1) according to the gradient, with 187 patients with MAS; and 2) accord-
ing to the AVA, with 187 patients with HG-SAS.
Results Patients with PLG-SAS had reduced overall survival (1-year: 89  2%; 5-year: 64  4%) compared with patients
with HG-SAS (1-year: 96  1%; 5-year: 82  3%) or MAS (1-year: 96  1%; 5-year: 81  3%). After adjustment
for other risk factors, patients with PLG-SAS had a 1.71-fold increase in overall mortality and a 2.09-fold in-
crease in cardiovascular mortality compared with the 2 other groups. Aortic valve replacement was significantly
associated with improved survival in the HG-SAS group (hazard ratio: 0.18; p  0.001) and in the PLG-SAS group
(hazard ratio: 0.50; p  0.04) but not in the MAS group.
Conclusions Prognosis of patients with paradoxical low-flow, low-gradient severe AS was definitely worse than those with
high-gradient severe AS or those with moderate AS. The finding of a low gradient cannot exclude the presence of
a severe stenosis in a patient with a small AVA and preserved LVEF and should mandatorily prompt further
investigation. (J Am Coll Cardiol 2012;60:1259–67) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2011.12.054According to American College of Cardiology/American
Heart Association and European Society of Cardiology
guidelines for the management of patients with valvular
heart disease, only patients having severe aortic stenosis
(AS) associated with either symptoms and/or left ventricular
ejection fraction (LVEF) 50% or undergoing coronary
artery bypass graft surgery or other cardiac surgery have a
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Severe AS is generally defined as an aortic valve area (AVA)
1.0 cm2 and a mean transvalvular gradient 40 mm Hg.
However, the clinician is often confronted with patients
having discordant findings (e.g., an AVA  0.8 cm2
consistent with the presence of a severe AS but a mean
gradient [MG]  30 mm Hg rather indicating the presence
of a moderate AS). This situation raises uncertainty with
regard to the actual severity of the stenosis as well as the
potential indication of AVR if the patient is symptomatic.
See page 1268
We reported that this discordance might be related to the
presence of a severe stenosis with concomitant “paradoxical”
low flow (i.e., reduced stroke volume and thus transvalvular
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(3,4). The transvalvular pressure
gradient is inversely related to
the square of AVA and directly
related to the square of flow.
Hence, a patient with severe AS
might nonetheless present with a
low gradient if his or her left ventric-
ular (LV) output is reduced, such as
is often the case in low-LVEF, low-
flow AS, and paradoxical low-flow
AS. Paradoxical low-flow, low-
gradient AS is found in approxi-
mately 10% to 25% of the popula-
tion with severe AS, and the results
of previous studies suggest that this
entity often reflects a more advanced
stage of the disease (3–7). However,
there are very limited data on the
outcome of patients with paradoxi-
cal low-flow, low-gradient AS and
on the potential clinical benefits of
AVR in these patients.
Other investigators also reported that the discordant
AVA-gradient findings might be due to inconsistency in the
guidelines criteria used to grade stenosis severity (8,9).
Indeed, when fitting together AVA and gradient data in
patients with normal transvalvular flow rates, it seems that
the AVA cutoff value of 1.0 cm2 proposed in the guidelines
o define severe stenosis corresponds to a value of gradient
hat is lower (30 to 35 mm Hg) than the 40 mm Hg
uidelines criteria (8). And finally, discordance between
VA and gradient might be related to the presence of small
ody size or errors in the Doppler-echocardiographic mea-
urements. In a recent substudy of the SEAS (Simvastatin and
zetimibe in Aortic Stenosis) trial, Jander et al. (9) reported
hat patients with low-gradient (i.e., 40 mm Hg) “severe”
i.e., AVA 1.0 cm2) AS and normal LVEF (50%) have
similar outcome when compared with that in patients with
moderate AS.
Therefore the objective of this case match study was to
compare the outcome of patients with paradoxical low-flow,
low-gradient, a priori severe aortic stenosis (PLG-SAS group)
with that of patients with a severe AS and consistent high-
gradient severe aortic stenosis (HG-SAS group) and with that
of patients with a moderate aortic stenosis (MAS group).
Methods
In a cohort of 1,589 consecutive AS patients with at least
moderate AS and preserved LVEF (50%), we retrospec-
tively identified 223 patients (14%) with paradoxical low-
flow (stroke volume index 35 ml/m2), low-gradient (MG
40 mm Hg), a priori severe (AVA 1.0 cm2 and indexed
VA 0.6 cm2·m2) AS (Fig. 1). Among this subset, 187
Abbreviations
and Acronyms
AS  aortic stenosis
AVA  aortic valve area
AVR  aortic valve
replacement
CI  confidence interval
HG-SAS group  patients
with high-gradient severe
aortic stenosis
HR  hazard ratio
LV  left ventricular
LVEF  left ventricular
ejection fraction
MAS group  patients with
moderate aortic stenosis
MG  mean gradient
PLG-SAS group  patients
with paradoxical low-flow,
low-gradient, a priori severe
aortic stenosispatients (PLG-SAS group) were matched: 1) according tothe gradient (3 mm Hg), with 187 patients with moderate
AS defined as an AVA 1.0 cm2 and an indexed AVA
0.6 cm2·m2 and representing the MAS group; and 2)
according to the AVA (0.05 cm2), with 187 patients with
severe AS documented by an AVA 1.0 cm2, an indexed
AVA 0.6 cm2·m2, and an MG 40 mm Hg represent-
ng the HG-SAS group (Fig. 1).
linical data. Clinical data included age, sex, documented
iagnosis of hypertension, hypercholesterolemia, diabetes, obesity
body mass index 30 kg·m2), and coronary artery disease (3).
ymptomatic status. Patients were classified as having no
ardiac symptoms, mild symptoms (dyspnea [New York
eart Association functional class II], angina [Canadian
ardiovascular Society class I or II], and/or fatigue), or
oderate/severe symptoms (dyspnea [New York Heart
ssociation functional class III or IV], angina [Canadian
ardiovascular Society class III or IV], and/or syncope).
oppler echocardiography. The Doppler-echocardiographic
easurements included the LV dimensions, the LVEF
alculated by the Simpson method, the peak and mean
ransvalvular pressure gradients obtained with the use of the
odified Bernoulli equation, and the AVA obtained with
he use of the standard continuity equation. We paid
articular attention to the search for the highest peak
ransvalvular velocity with the use of multi-window
ontinuous-wave Doppler interrogation. The Doppler-
chocardiographic measurement of LV outflow tract stroke
olume was corroborated by the 2-dimensional volumetric
r Teicholz method. As a measure of global LV hemody-
amic load, we calculated the valvulo-arterial impedance:
va (SAPMG)/SVI, where SAP is the systolic arterial
pressure, MG the mean transvalvular pressure gradient, and
SVI the stroke volume indexed to body surface area (10).
Study endpoints. The primary endpoints for this study were
overall and cardiovascular mortality, regardless of whether or
not there was AVR. Hence, this includes the deaths occurring
in patients who did not undergo AVR as well as those
occurring after operation in patients who underwent AVR.
The outcome data were retrospectively obtained from the
charts or death certificates of patients. The secondary end-
points were AVR and the combined endpoint of AVR and
overall death. Figure 1 shows the reasons for therapeutic
decision making as reported in the patient’s chart.
Statistical analysis. Results are expressed as mean SD or
percentages. For continuous variables, differences between
groups were analyzed with the use of 1-way analysis of
variance for repeated measures followed by the Tukey’s post
hoc test for inter-group comparisons. The Cochran-
Mantel-Haenszel test was used to compare categorical
variables as appropriate.
Cumulative survival was estimated with the stratified
Kaplan-Meier method and compared between groups with
a log-rank test. The effect of the clinical and Doppler-
echocardiographic variables on survival and event-free sur-
vival was assessed with the use of stratified Cox proportional
hazard models. The impact of AVR during follow-up was
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October 2, 2012:1259–67 Outcome of Low-Gradient Preserved EF Severe Aortic Stenosistested with AVR as a time-dependent covariate in the
stratified Cox proportional hazards model for overall and
cardiovascular survival. Age, sex and clinically relevant
variables with a p value 0.05 on univariable analysis were
ncorporated into the multivariable models.
A propensity score representing the probability of having
VR as opposed to conservative therapy was calculated for
ach patient with a logistic regression analysis that identified
ariables independently associated with the type of proce-
Figure 1 Study Flow Chart
The numbers in bold represent the total number and percentage of patients in eac
tic valve area; AVR  aortic valve replacement; LVEF  left ventricular ejection fraure. The calculated propensity score was then incorporatedinto subsequent multivariable regression models. Data were
analyzed by SPSS for Windows (version 19.0, SPSS, Inc.,
Chicago, Illinois).
Results
Baseline characteristics. Compared with patients in HG-SAS
and MAS groups, patients with PLG-SAS were older and had
a higher proportion of women; higher prevalence of coronary
tment group. AS  aortic stenosis; AVA  aortic valve area; AVAi  indexed aor-
MG  mean gradient; SVi  stroke volume index.h trea
ction;artery disease and hypertension; higher valvulo-arterial im-
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LV end-diastolic volume, stroke volume, and transvalvular
flow rate (Table 1). They also had higher prevalence of diabetes
compared with the HG-SAS group. The prevalence of
moderate/severe symptoms was similar in the PLG-SAS
(56%) and HG-SAS (58%) groups but lower in the MAS
group (32%).
Clinical outcomes. During a mean follow-up of 4.2  2.4
years, there were 307 AVRs (Fig. 1) and 127 deaths, of
which 82 were cardiovascular-related. Among the patients
who underwent AVR, the proportion of concomitant cor-
onary artery bypass graft surgery was similar in the 3 groups:
39% in the HG-SAS group, 53% in the PLG-SAS group,
and 43% in the MAS group (p  0.13). Combined (AVR
or death) event-free survival rates at 1- and 5-year follow-up
were 63  4% and 24  4%, respectively, for PLG-SAS
roup versus 30  3% and 9  3% for the HG-SAS group
nd 85  3% and 41  4% for the MAS group (p 
.0001) (Fig. 2A). Patients with PLG-SAS had lower
Clinical and Doppler-Echocardiographic DataTable 1 Clinical and Doppler-Echocardiographic Data
Variables
HG-SAS
(n  187)
Clinical data
Female 59 (31)*
Age, yrs 66 15*
Body surface area, m2 1.85 0.21*
Body mass index, kg·m2 27 5
Heart rate, beats·min1 66 12*
Systolic blood pressure, mm Hg 129 22
Diastolic blood pressure, mm Hg 72 11
Obesity 50 (27)
Hypertension 122 (65)*
Diabetes 30 (16)*‡
Dyslipidemia 92 (49)
Coronary artery disease 85 (45)*
Previous cerebrovascular event 21 (11)
Symptoms
None 50 (27)‡
Mild symptoms 28 (15)‡
Moderate/severe symptoms 109 (58)‡
Doppler-echocardiographic data
LV end-diastolic volume, ml 110 31*
LV end-diastolic volume index, ml·m2 59 15*
LV ejection fraction, % 67 7*‡
Stoke volume, ml 87 17*
Stoke volume index, ml·m2 47 8*
Mean transvalvular flow rate, ml·s1 272 53*
Peak aortic jet velocity, m·s1 4.5 0.5*‡
Peak gradient, mm Hg 83 18*‡
Mean gradient, mm Hg 50 10*‡
Aortic valve area, cm2 0.82 0.16‡
Indexed aortic valve area, cm2·m2 0.45 0.08‡
Valvulo-arterial impedance, mm Hg·ml1·m2 3.88 0.79*‡
Values are n (%) or mean SD. *Significant difference between patients with high-gradient severe a
(PLG-SAS) groups. †Significant difference between moderate aortic stenosis (MAS) and PLG-SAS
LV  left ventricular.ncidence of AVR (1-year: 29  3%; 5-year: 55  5%) iompared with HG-SAS patients (1-year: 69 3%; 5-year:
5  3%) but higher incidence compared with MAS
atients (1-year: 12  2%; 5-year: 47  5%) (Fig. 2B).
atients with PLG-SAS had reduced overall survival (1-
ear: 89  2%; 5-year: 64  4%) (Fig. 2C) and cardiovas-
ular survival (1-year: 91  2%; 5-year: 74  4%) (Fig. 2D)
ompared with patients with HG-SAS (overall: 1-year:
6  1%; 5-year: 82  3%; cardiovascular: 1-year: 97  1%;
-year: 85  3%) or MAS (overall: 1-year: 96  1%; 5-year:
1  3%; cardiovascular: 1-year: 98  1%; 5-year: 91  2%).
redictors of outcomes. In multivariable analysis, the
actors associated with increased risk of combined events
AVR or death) were: higher MG (p  0.0001), coronary
rtery disease (p  0.001), moderate/severe symptoms (p 
.02), obesity (p  0.002), female sex (p  0.04), and
igher valvulo-arterial impedance (p  0.004) (Table 2).
The factors independently associated with increased over-
ll mortality were older age (p  0.0001), conservative
reatment (p  0.0001), lower LVEF (p  0.03), and being
PLG-SAS
(n  187)
MAS
(n  187) p Value
96 (51)*† 67 (36)† 0.0001
74 12*† 67 13† 0.001
1.80 0.24*† 1.85 0.24† 0.015
27 6 27 5 0.90
71 13* 67 13 0.005
132 21 132 21 0.28
73 11 72 11 0.86
46 (25) 56 (30) 0.28
146 (78)*† 127 (68)† 0.012
55 (29)* 47 (25)‡ 0.021
111 (59) 101 (54) 0.29
120 (64)*† 83 (44)† 0.0001
23 (12) 21 (11) 0.45
41 (22)† 73 (39)†‡
42 (22) 55 (29)‡ 0.0001
104 (56)† 59 (32)†‡
92 24*† 106 26† 0.0001
51 12.0*† 58 13† 0.0001
62 8*† 65 7†‡ 0.0001
55 10*† 86 16† 0.0001
30 4*† 46 8† 0.0001
176 34*† 274 52† 0.0001
3.0 0.5* 3.0 0.5‡ 0.0001
39 13* 39 14‡ 0.0001
22 8* 22 8‡ 0.0001
0.82 0.16† 1.30 0.19†‡ 0.0001
0.45 0.09† 0.71 0.10†‡ 0.0001
5.14 1.17*† 3.41 0.73†‡ 0.0001
enosis (HG-SAS) and patients with paradoxical low-flow, low-gradient, a priori severe aortic stenosis
‡Significant difference between HG-SAS and MAS groups.ortic stn the PLG-SAS group (p  0.02) (Table 3). After
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disease, diabetes, type of treatment, and LVEF, patients
with PLG-SAS had a 1.88-fold increase in overall mortality
(Table 3) and 2.87-fold increase in cardiovascular mortality
(Table 4) compared with patients with MAS. When com-
Figure 2 Kaplan-Meier Analysis of Combined Events, AVR, Ove
Kaplan-Meier analysis of combined (aortic valve replacement [AVR], or death) events (
bers at the bottom of the graph represent the number of patients at risk at each follow-u
Cox proportional hazard model). *Statistically significant difference (p  0.05) from mode
MAS group  patients with moderate aortic stenosis; PLG-SAS group  patients with para
Univariable and Multivariable Analyses of Combined (AVR or DeathTable 2 Univariable and Multivariable Analyses of Combined (A
Variables
Univariable Analysis
HR 95% CI
Age (per 1-yr increase) — —
Female — —
Symptoms
None Referent
Mild 1.22 0.76–1.94
Moderate/severe 3.20 2.12–4.84
Coronary artery disease 1.48 1.11–1.97
Group
MAS group Referent
PLG-SAS group 1.69 1.30–2.19
HG-SAS group 3.88 3.01–4.99This table includes age and sex (forced into the models) and the variables that were significant (p  0.0
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.pared with HG-SAS and MAS patients pooled together,
PLG-SAS patients had a 1.71-fold (95% confidence inter-
val [CI]: 1.07 to 2.71; p  0.02) and 2.09-fold (95% CI:
1.16 to 3.78; p 0.01) increase in overall and cardiovascular
mortality, respectively.
urvival, and Cardiovascular Survival
R (B), overall survival (C), and cardiovascular survival (D) in the 3 groups. The num-
. The p value between brackets is the p value adjusted for other risk factors (stratified
rtic stenosis (MAS). HG-SAS group  patients with high-gradient severe aortic stenosis;
l low-flow, low-gradient, a priori severe aortic stenosis.
nt-Free Survivalr Death) Event-Free Survival
Multivariable Analysis
Value HR 95% CI p Value
0.49 — — 0.35
0.12 0.64 0.41–0.99 0.04
Referent
0.41 — — 0.36
0.0001 2.84 1.74–4.63 0.0001
0.007 — — 0.51
Referent
0.0001 2.11 1.41–3.15 0.0001
0.0001 5.82 3.92–8.64 0.0001rall S
A), AV
p year
rate ao
doxica) EveVR o
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
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ssociated with significantly better survival in the 3 groups
Fig. 3). The magnitude of the protective effect of AVR
eemed to be more important in the HG-SAS and PLG-
AS groups compared with the MAS group. Age, LVEF,
ody surface area, peak aortic jet velocity, AVA, coronary
rtery disease, and presence of moderate/severe symptoms
ere independently associated with the type of treatment
nd were used for the calculation of the propensity score
Hosmer-Lemeshow Statistic: p  0.997). After adjusting
for age and propensity score, AVR was associated with
improved survival in the whole cohort (hazard ratio [HR]:
0.35; 95% CI: 0.21 to 0.56, p  0.0001) as well as in the
HG-SAS group (HR: 0.18; 95% CI: 0.07 to 0.48, p 
0.001) and PLG-SAS group (HR: 0. 50; 95% CI: 0.25 to
Univariable and Multivariable Analyses of Overall MortalityTable 3 Univariable and Multivariable Analyses of Overall Mort
Variables HR
Age (per 1-yr increase) 1.07
Female —
Symptoms
None Referent
Mild —
Moderate/severe —
Coronary artery disease 1.86
LV ejection fraction (per 5% increase) 0.75
Aortic valve replacement* 0.35
Valvulo-arterial impedance (per 1 mm Hg·ml1·m2 increase) 1.27
Group
MAS group Referent
PLG-SAS group 2.03
HG-SAS group —
This table includes age and sex (forced into the models) and the variables that were significant (p
Abbreviations as in Tables 1 and 2.
Univariable and Multivariable Analyses of Cardiovascular MortalityTable 4 Univariable and Multivariable Analyses of Cardiovascul
Variables HR
Age (per 1-yr increase) 1.08
Female —
Symptoms
None Referent
Mild 2.65
Moderate/severe 2.22
Coronary artery disease 1.83
LV ejection fraction (per 5% increase) 0.78
Aortic valve replacement* 0.41
Valvulo-arterial impedance (per 1 mm Hg·ml1·m2 increase) 1.66
Group
MAS group Referent
PLG-SAS group 2.43
HG-SAS group —
This table includes age and sex (forced into the models) and the variables that were significant (p
was used as a time-dependent variable.
Abbreviations as in Tables 1 and 2.0.99, p 0.04), and there was also a trend for an association
between AVR and improved survival in MAS group (HR:
0.44; 95% CI: 0.17 to 1.12, p  0.09).
Discussion
The main findings of this study are that patients with
PLG-SAS have worse prognosis compared with patients
with MAS as well as those with HG-SAS, and the outcome
of these patients with PLG-SAS is improved by AVR.
Compared with patients with MAS or HG-SAS, patients
with PLG-SAS had a higher prevalence of female sex and
hypertension and had smaller LV cavities and markedly
higher valvulo-arterial impedance. These typical features are
consistent with the presence of paradoxical low-flow severe
riable Analysis Multivariable Analysis
95% CI p Value HR 95% CI p Value
1.04–1.10 0.0001 1.05 1.02–1.07 0.001
— 0.27 — — 0.60
— 0.09 — — —
— 0.15 — — —
1.14–3.04 0.01 — — 0.58
0.64–0.87 0.0001 — — 0.09
0.21–0.61 0.0001 0.32 0.15–0.67 0.002
1.12–1.44 0.0001 — — 0.10
Referent
1.35–3.05 0.001 1.88 1.05–3.37 0.03
— 0.48 — — 0.06
5) on univariable analyses. *Aortic valve replacement was used as a time-dependent variable.
ortality
iable Analysis Multivariable Analysis
95% CI p Value HR 95% CI p Value
.04–1.12 0.0001 1.05 1.01–1.09 0.02
— 0.46 — — 0.55
Referent
.06–6.59 0.04 — — 0.90
.00–5.06 0.55 — — 0.29
.01–3.32 0.04 — — 0.71
.65–0.93 0.007 — — 0.33
.21–0.79 0.0008 0.31 0.11–0.85 0.02
.17–2.36 0.005 — — 0.41
Referent
.55–3.80 0.0001 2.87 1.24–6.45 0.01
— 0.46 — — 0.06
) on univariable analyses. HR  hazard ratio; CI  confidence interval. *Aortic valve replacementality
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October 2, 2012:1259–67 Outcome of Low-Gradient Preserved EF Severe Aortic StenosisAS, a clinical entity that we initially described in 2007 (3).
Several other studies have subsequently confirmed that
paradoxical low-flow AS often corresponds to a more
advanced stage of the disease as reflected by more severe
intrinsic myocardial damage and the appearance of a restric-
tive physiology, which in turn contributes to the low-flow
state in these patients despite the presence of a preserved
LVEF (5–7,11,12). Hence, the worse outcome observed in
patients with PLG-SAS is likely due to the combination of
more advanced age, more frequent comorbidities such as
hypertension, worse intrinsic myocardial damage, and lesser
referral to surgery. With regard to this latter aspect, it
should be emphasized that the presence of a low gradient in
a patient with preserved LVEF might lead the treating
physician to conclude that the stenosis is not severe even if
the AVA is 1.0 cm2. Hence, among 2 patients having a
mall AVA, a preserved LVEF, and moderate cardiac
ymptoms, it is likely that the one with a high gradient (e.g.,
0 mm Hg) would promptly be referred to surgery, whereas
here would be much questioning with regard to the other
atient with a moderate gradient (e.g., 30 mm Hg). Current
ractice guidelines indeed put a lot of emphasis on the
radient (or the peak aortic jet velocity) in the decision to
efer a patient to AVR. Accordingly, in the present study,
atients with small AVA and low gradient (i.e., with
LG-SAS) were less often referred to surgery compared
ith those with small AVA and high-gradient (i.e., HG-
AS), although they had similar AVA and prevalence of
oderate/severe symptoms (Table 1, Fig. 1). However, the
atients with PLG-SAS had significantly reduced overall
nd cardiovascular survival even after adjustment for the
ifferences in the baseline risk factors. Furthermore, the
erformance of AVR was highly protective in this subset of
Figure 3 Kaplan-Meier Curves of Overall Survival According
the Group of Patients and Type of Treatment
Kaplan-Meier curves of overall survival according the group of patients and
type of treatment: AVR versus Conservative (Cons). Abbreviations as in Figure 2.atients even after adjustment for propensity score. Hence, ehe PLG-SAS entity is often misdiagnosed, which leads to
nderestimation of stenosis severity and symptoms and
herefore under-use or inappropriate delay of AVR.
A previous paradigm was that normal LVEF implies
ormal stroke volume and transvalvular flow rate. However,
t is now well-established that an important proportion of
atients with cardiovascular diseases might have a reduced
V pump function despite preserved LVEF. This phenom-
non is related to pronounced LV concentric remodeling
ith reduced cavity size, increased myocardial fibrosis,
mpaired diastolic filling, increased afterload, and altered
yocardial systolic function unrevealed by LVEF. This
ow-flow state condition might considerably complicate the
ssessment of stenosis severity in patients with AS, because
he main stenotic index used for clinical decision making,
amely the gradient, is directly related to the squared
unction of transvalvular flow rate. Hence, even a modest
ecrease in flow rate could yield to important reduction in
radient and thus to underestimation of stenosis severity. In
he present study, patients with PLG-SAS had a much
ower transvalvular flow rate when compared with the 2
ther groups. The transvalvular gradient and peak aortic jet
elocity have a high specificity to identify severe AS.
owever, because patients with severe AS often have a
educed stroke volume and transvalvular flow rate irrespective
f LVEF, these parameters might be quite lower than expected
n an important proportion of patients, thus resulting in
elatively low sensitivity. These findings raise the importance of
onsidering other Doppler-echocardiographic parameters and
ventually other diagnostic tests when confronted with
iscordance between AVA (in the severe range) and gradi-
nt (in the moderate range).
In the present study, we elected to include both asymp-
omatic and symptomatic patients, because this approach
etter reflects the clinical spectrum of the disease. More-
ver, the most challenging patient subset from both a
iagnostic and a therapeutic standpoint is precisely the one
ith discordant echocardiographic findings and symptoms.
n this subset, it is crucial to confirm stenosis severity to
elect the most appropriate treatment: AVR versus conser-
ative therapy. The presence and severity of symptoms is
ifficult to assess and interpret in elderly patients, which
epresent the majority of the AS population today. In the
resent study, moderate-to-severe symptoms were powerful
redictors of the composite of AVR or death but were not
ignificantly associated with overall mortality. Thus these
ndings emphasize the point that the main parameters (i.e.,
G, peak jet velocity, symptoms, and LVEF) on which
herapeutic decisions are predominantly based in current
ractice have important limitations and that some patients
ight nonetheless have severe AS despite the presence of
ow gradient and preserved LVEF.
The primary goal of therapeutic management in AS is to
mprove longevity and quality of life. Accordingly, we
elected overall and cardiovascular mortality as the primary
ndpoints for this study. Previous studies have generally
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often the sole endpoint, and when such is the case, this
composite endpoint is in very large part driven by AVR (9).
However, the limitation of this endpoint is that it is
essentially determined by the perception of disease severity
by the clinician, which is in turn highly influenced by the
magnitude of the gradient (or peak aortic jet velocity) and by
the presence of symptoms. Hence, it is not surprising that
these parameters are often found to be powerful predictors
of this composite endpoint (i.e., they are the reasons why
the cardiologist refers the patient to AVR). The findings of
the present study underline the importance of not only
reporting the composite of AVR or death but also the
overall and cardiovascular mortality, regardless of the type of
treatment. As a matter of fact, patients with PLG-SAS had
lower incidence of the composite of AVR or death when
compared with HG-SAS (Fig. 2A), but the reverse was
observed when analyzing overall and cardiovascular mortal-
ity (Figs. 2C and 2D). Indeed, survival was markedly lower
in the PLG-SAS group, whereas it was similar in the MAS
and HG-SAS groups. And this difference persisted after
adjustment for other risk factors.
At first glance, the results of the present study are
discordant with those of the recent study by Jander et al. (9)
reporting that patients with low-gradient severe (i.e., small
AVA) AS and preserved LVEF have an outcome similar to
that in patients with moderate AS. However, the results of
Jander et al. do not correspond to the PLG-SAS entity that
we specifically examined in this study. Indeed, the low-
gradient severe AS patients reported by Jander et al. (9) do
not exhibit the features typically observed in patients with
paradoxical low-flow AS, and as recently discussed (13), the
finding of low-gradient severe AS in these cases could rather
be due to 1 or more of the following: 1) small body size;
2) measurement errors; and 3) inconsistent grading due to
intrinsic discrepancies in guidelines criteria. This interpre-
tation is further comforted by the results of a previous
substudy from the SEAS trial, whereby, in the same cohort
of patients, Cramariuc et al. (11) identified 100 low-flow
patients with the stroke volume measured by volumetric
method rather than the 223 reported by Jander et al. (9), and
these patients also exhibited the restrictive features usually
associated with paradoxical low-flow AS.
Clinical implications. The findings of this study empha-
size the importance of not systematically denying surgery to
a symptomatic patient with small AVA and low gradient.
Indeed, the presence of these discordant findings in a
patient with preserved LVEF should not be automatically
equated with a moderate AS but rather be conducive to a
more comprehensive Doppler-echocardiographic evaluation
and potentially to the performance of other diagnostic
modalities if the results of the echocardiographic evaluation
remain inconclusive with regard to stenosis severity. Hence,
the first steps when confronted with discordance between
AVA and gradient should be: 1) to rule out potential errors
in the measurement of stroke volume, AVA, and/or gradi- sents as emphasized in the recent American Society of
Echocardiography/European Association of Echocardiog-
raphy recommendations (14); 2) to rule out the confounding
effect of small body size by calculating the indexed AVA, a
value 0.6 cm2/m2 being indicative of the presence of
oderate AS; and 3) to establish whether the global
emodynamic load is severely increased (i.e., valvulo-arterial
mpedance4.5 mm Hg·ml1·m2), as is often the case with
LF-SAS (15). The next step could then be to assess the
ymptomatic status of the patient and, if the patient claims
o be asymptomatic, to perform an exercise test. Corrobo-
ating methods including dobutamine stress echocardiogra-
hy, valve calcium quantification by computed tomography,
nd dosage of plasma B-type natriuretic peptide can also be
sed to confirm the presence of a severe stenosis as well as
o determine the indication for surgery.
Owing to their particular LV geometry/function pattern
i.e., small LV cavity with pronounced concentric remodel-
ng and restrictive physiology, and often small LV outflow
ract and aortic annulus), patients with PLG-SAS might
ave increased risk of perioperative mortality/morbidity
Fig. 3) and prosthesis-patient mismatch after surgical
VR. Thus further studies are needed to determine the
otential value of transcatheter aortic valve implantation in
his particular subset of patients.
Of note, patients with moderate AS also had a relatively
igh event rate. This finding is in agreement with several
ecent studies (16,17) suggesting that moderate AS is not a
enign disease. Hence, closer follow-up should be consid-
red in these patients with moderate AS, and the 2-year
nterval proposed in the guidelines is probably too long.
tudy limitations. The main limitation of this study is its
etrospective design. The baseline data were prospectively
ollected in consecutive patients with AS referred to the
chocardiographic laboratory. However, the outcome data
ere retrospectively obtained from the charts or death
ertificates of patients. Some variables previously reported as
eing risk factor or risk of disease progression (i.e., LV
ongitudinal strain, left atrial volume, B-type natriuretic
eptide, and valve calcification) were not measured in this
tudy, thus limiting the characterization of the different
tudy groups.
onclusions
rognosis of PLG-SAS patients was worse than those with
igh-gradient severe AS and those with moderate AS.
urthermore, the outcome of these patients with PLG-SAS
as improved by surgical treatment. Hence, the finding of a
ow gradient should not exclude the presence of a severe
tenosis in a patient with a small AVA and preserved
VEF. When confronted with this situation, a more com-
rehensive Doppler-echocardiographic evaluation as well as
ther diagnostic tests should be used to corroborate the
tenosis severity and guide therapeutic management.
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